Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia

Reviva Pharmaceuticals Holdings ( (RVPH) ) has issued an update.

On June 2, 2025, Reviva Pharmaceuticals announced the successful completion of its Phase 3 RECOVER open-label extension study, which evaluated the long-term safety, tolerability, and efficacy of brilaroxazine in schizophrenia patients. The study showed sustained broad-spectrum efficacy over one year with a 35% discontinuation rate, mostly due to withdrawal of consent. Brilaroxazine, a serotonin dopamine signaling modulator, demonstrated a well-tolerated safety profile with no serious adverse events related to the drug, supporting its potential for addressing unmet needs in schizophrenia treatment.

The most recent analyst rating on (RVPH) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.

Spark’s Take on RVPH Stock

According to Spark, TipRanks’ AI Analyst, RVPH is a Underperform.

Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.

To see Spark’s full report on RVPH stock, click here.

More about Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system, inflammatory, and cardiometabolic diseases.

Average Trading Volume: 685,781

Technical Sentiment Signal: Sell

Current Market Cap: $45.35M

Learn more about RVPH stock on TipRanks’ Stock Analysis page.